BMN 333 Updated Nov 2
The next catalyst for BMN 333 is dose-response data from the Phase 2/3 dose-finding segment, expected in 2027 (no specific date given). Positive data would validate a weekly, potentially superior alternative to Voxzogo and strengthen BioMarin's achondroplasia franchise against Ascendis' newly approved Yuviwel. Negative or underwhelming data would raise doubts about the drug's best-in-class potential and could pressure BMRN shares given the competitive threat.
- Phase 1 data showed BMN 333 achieved >13x higher free CNP exposure versus another long-acting CNP agent, with favorable safety and no dose-limiting toxicities, supporting once-weekly dosing.
- BioMarin management describes BMN 333 as a 'potential best-in-class molecule' with opportunity to drive greater improvements in growth parameters versus available therapies.
- BMN 333 is designed as a weekly subcutaneous injection versus Voxzogo's daily injection, a significant convenience advantage that could drive patient and physician adoption.
- Ascendis Pharma's Yuviwel (navepegritide) was FDA-approved on February 27, 2026 as the first once-weekly CNP for achondroplasia, establishing a direct competitive head start while BMN 333 is still in Phase 2/3 trials.
- BMN 333 is years from potential approval (estimated launch around 2030 per earlier BioMarin guidance), giving competitors time to capture market share.
- The Phase 2/3 trial is active-controlled against BioMarin's own Voxzogo, creating a high bar: the drug must demonstrate superiority or at least non-inferiority with less frequent dosing to justify switching.